T4K3.news

Rush begins offering new cancer detection blood test

The Galleri blood test, capable of identifying over 50 cancers, is now available at Rush.

July 26, 2025 at 11:00 AM

Rush offers blood test to detect more than 50 cancers

A new blood test aims to detect cancers early, but concerns loom over its readiness and cost.

Rush starts offering new blood test for early cancer detection

Rush University System for Health has begun offering a blood test that claims to detect over 50 types of cancer. This test, called Galleri, uses DNA from cancer cells found in the bloodstream. Participants, like Jack Welter, who underwent successful treatment thanks to early detection, highlight its potential benefits. However, the test is not FDA approved, costing patients $749 out-of-pocket, which raises concerns about its accessibility and effectiveness. Some healthcare providers express caution, citing insufficient sensitivity and potential for false positives. Studies show mixed results, leaving room for debate about its role in routine screenings.

Key Takeaways

✔️

Galleri claims to detect over 50 types of cancer through a simple blood test.

✔️

Jack Welter's experience underscores the test's potential for early detection.

✔️

The blood test costs $749 and is not covered by most insurance plans.

✔️

Concerns exist about the FDA approval status and overall test reliability.

✔️

Healthcare providers remain cautious, citing issues with sensitivity and specificity.

✔️

Early detection is critical, but the test's accessibility could create disparities.

"Without that test, I still would have had cancer, obviously, but it might not have appeared for another year or more."

Jack Welter shares how early detection benefited him greatly after taking the Galleri test.

"I just don’t think we’re there yet."

Genetic counselor Feighanne Hathaway expresses concerns about the readiness of the Galleri test.

"We can look for all the other cancers that are taking people’s lives."

Dr. Joshua Ofman emphasizes the importance of detecting cancers beyond the currently recommended screenings.

"For one, I worry that the out-of-pocket cost creates more disparities in health care."

Feighanne Hathaway raises a valid concern over the test's accessibility for different patient populations.

The introduction of the Galleri test marks a significant moment in cancer detection technology, but it also reveals the complexities of healthcare innovation. Although some patients and doctors are optimistic about its potential to save lives, the lack of FDA approval and the associated costs may deter many individuals. Moreover, the risk of false positives could lead to unnecessary anxiety and further testing, which adds to the burden of those already concerned about their health. As healthcare continues to evolve, balancing innovation with practicality and accessibility will be crucial.